Furberg C D, May G S
Am J Med. 1984 Jun 22;76(6A):76-83. doi: 10.1016/0002-9343(84)91047-7.
Survivors of the acute phase of a myocardial infarction still have an increased risk of dying, primarily due to causes directly attributable to their coronary heart disease. This review of randomized clinical trials of various interventions with the potential to prolong life in these patients is an attempt to answer a vitally important question. What, if anything, can be done to improve the long-term prognosis in patients who have survived the initial one or two weeks after suffering an acute myocardial infarction? Seven classes of intervention are considered: anticoagulants, platelet-active drugs, lipid-lowering regimens, antiarrhythmic agents, physical exercise, calcium antagonists and beta-blockers. So far only beta-blockers have been shown to have a favorable effect on long-term survival. Many of the trials reviewed had design limitations; in particular, the sample size was often too small for the results to be conclusive.
心肌梗死急性期的幸存者仍有较高的死亡风险，主要是由于直接归因于其冠心病的原因。对各种可能延长这些患者生命的干预措施进行的随机临床试验综述，旨在回答一个至关重要的问题。对于在急性心肌梗死发作后的最初一两周内存活下来的患者，能做些什么（如果有的话）来改善其长期预后？考虑了七类干预措施：抗凝剂、血小板活性药物、降脂方案、抗心律失常药物、体育锻炼、钙拮抗剂和β受体阻滞剂。到目前为止，只有β受体阻滞剂被证明对长期生存有有利影响。所综述的许多试验存在设计缺陷；特别是，样本量往往过小，以至于结果无法定论。
